BC
Birchview Capital Portfolio holdings
AUM
$101M
This Quarter Return
-0.71%
1 Year Return
+34.62%
3 Year Return
+103.2%
5 Year Return
+107.72%
10 Year Return
+352.1%
AUM
$108M
AUM Growth
+$108M
(-12%)
Cap. Flow
-$5.67M
Cap. Flow
% of AUM
-5.24%
Top 10 Holdings %
Top 10 Hldgs %
67.6%
Holding
63
New
4
Increased
7
Reduced
9
Closed
3
Top Buys
| 1 |
Corcept Therapeutics
CORT
|
$780K |
| 2 |
Prothena Corp
PRTA
|
$702K |
| 3 |
Exxon Mobil
XOM
|
$673K |
| 4 |
Biodesix
BDSX
|
$531K |
| 5 |
Castle Biosciences
CSTL
|
$435K |
Top Sells
| 1 |
Neurocrine Biosciences
NBIX
|
$4.82M |
| 2 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$1.69M |
| 3 |
PXD
Pioneer Natural Resource Co.
PXD
|
$998K |
| 4 |
Bristol-Myers Squibb
BMY
|
$639K |
| 5 |
Elutia
ELUT
|
$514K |
Sector Composition
| 1 | Healthcare | 94.57% |
| 2 | Energy | 5.43% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Inhibrx
INBX
$408M
| $171K | 0.16% |
+12,110
| New | +$171K |
|
52
Gossamer Bio
GOSS
$562M
| $124K | 0.12% |
138,176
| – | – |
|
53
Liquidia Corp
LQDA
$2.38B
| $120K | 0.11% |
10,000
| – | – |
|
54
InflaRx
IFRX
$108M
| $87K | 0.08% |
50,000
| – | – |
|
55
Cabaletta Bio
CABA
$133M
| $74.8K | 0.07% |
10,000
| – | – |
|
|
TSVT
56
DELISTED
2seventy bio
TSVT
| $68.7K | 0.06% |
17,833
-2,000
| -10% | -$7.7K |
|
57
Ventyx Biosciences
VTYX
$171M
| $66.5K | 0.06% |
28,800
| – | – |
|
58
Zentalis Pharmaceuticals
ZNTL
$122M
| $65.4K | 0.06% |
16,000
| – | – |
|
59
Outset Medical
OM
$247M
| $38.5K | 0.04% |
+10,000
| New | +$38.5K |
|
60
CERo Therapeutics
CERO
$9.06M
| $3.88K | ﹤0.01% |
12,972
| – | – |
|
|
PXD
61
DELISTED
Pioneer Natural Resource Co.
PXD
| – | – |
-3,800
| Closed | -$998K |
|
|
YTEN
62
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
| – | – |
-18,750
| Closed | -$7.13K |
|
|
INBX
63
DELISTED
Inhibrx, Inc. Common Stock
INBX
| – | – |
-48,448
| Closed | -$1.69M |
|